Tandem Duplications of the <i>UBTF</i> gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
Julia-Annabell Georgi(University Hospital Carl Gustav Carus), Christian Thiede(University Hospital Carl Gustav Carus), Mathias Haenel(Klinikum Chemnitz), Hermann Einsele(Universitätsklinikum Würzburg), Gerhard Ehninger(University Hospital Carl Gustav Carus), Markus Schaich(Rems-Murr-Klinikum), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Utz Krug(Klinikum Leverkusen), Sebastian Scholl(Jena University Hospital), Wolfgang E. Berdel(University Hospital Münster), Björn Steffen(Goethe University Frankfurt), Christoph Röllig(University Hospital Carl Gustav Carus), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Andreas Hochhaus(Jena University Hospital), Martin Bornhaeuser(German Cancer Research Center), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Andreas Neubauer(RWTH Aachen University), Marita Hartwig(University Hospital Carl Gustav Carus), Kerstin Schaefer-Eckart(Nuremberg Hospital), Christoph Schliemann(University Hospital Münster), Andreas Burchert(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Sebastian Stasik(University Hospital Carl Gustav Carus), Frank Kroschinsky(University Hospital Carl Gustav Carus), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Richard Noppeney(Essen University Hospital), Hubert Serve(Goethe University Frankfurt), Tim Sauer(Heidelberg University), Martin Kaufmann(Robert Bosch Hospital), Johannes Schetelig(University Hospital Carl Gustav Carus), Ralph Naumann(University of Siegen), Sven Zukunft(University Hospital Carl Gustav Carus)
Cited by 0
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k